

### Transcript Details

This is a transcript of an educational program. Details about the program and additional media formats for the program are accessible by visiting: <https://reachmd.com/programs/project-oncology/endometrial-cancer-molecular-target-therapies/39933/>

### ReachMD

www.reachmd.com  
info@reachmd.com  
(866) 423-7849

---

Advancing Endometrial Cancer Care: Molecular Targets and Emerging Therapies

### ReachMD Announcer:

You're listening to *Project Oncology* on ReachMD. On this episode, we'll hear from Dr. Casey Cosgrove, who's an Assistant Professor in the Department of Gynecologic Oncology at The Ohio State University College of Medicine and a member of the Translational Therapeutics Program at The Ohio State University Comprehensive Cancer Center. He'll be discussing evolving therapeutic approaches under investigation for endometrial cancer. Here's Dr. Cosgrove now.

### Dr. Cosgrove:

Beyond immunotherapy, there's a lot of excitement with different agents, whether they're also immune-based type treatments, like cellular therapies, T-cell therapies, or bispecifics. There's the antibody-drug conjugate class, which is expanding rapidly across the field of oncology, and endometrial cancer is benefiting from that.

And these approaches can also be tumor agnostic. So when we have markers that work for cancer across the board, it gives us an opportunity in the field of oncology to have agents that are going to be more tailored towards biomarkers as opposed to actual tumors themselves.

Endometrial cancer also has the opportunity to really benefit from more novel hormonal approaches, and so looking at some different strategies—especially for those lower-grade tumors—how can we have the least amount of side effects with the biggest amount of cancer efficacy from hormones? So I think there's a lot of really intriguing opportunities for us.

I think as we incorporate molecular classification within endometrial cancer, there's going to be different therapies that have differential benefits related to what we're finding on molecular classes. And within each molecular class, there's probably subgroups that may or may not benefit from certain therapies.

Right now, we're at this crossroads where we have to think about endometrial cancer not as just one disease site, but as several different disease sites based off of what their molecular profiles are telling. And probably, there are some therapies that may provide some great benefit for subgroups of endometrial cancers but not across the whole disease site of endometrial cancer. So we are going to have to be very smart as we're designing clinical trials as well as interpreting data to look for exploratory analyses that might suggest who might benefit from some of these really new, exciting therapeutic opportunities.

### ReachMD Announcer:

That was Dr. Casey Cosgrove discussing next-generation therapies for endometrial cancer. To access this and other episodes in our series, visit *Project Oncology* on ReachMD.com, where you can Be Part of the Knowledge. Thanks for listening!